Dosage
For Subcutaneous Administration
Do
not inject intravascularly.
Indications and Dosing
VARIVAX is indicated for vaccination against varicella in individuals 12
months of age and older.
| — |
Children 12 months to 12 years of age should receive a 0.5-mL dose
administered subcutaneously; if a second 0.5-mL dose is administered, it should
be given a minimum of 3 months later.
|
| — |
Adolescents and adults 13 years of age and older should receive a
0.5-mL
dose administered subcutaneously at elected date and a second 0.5-mL dose 4 to
8
weeks later.1 |
Select Safety Information
VARIVAX is contraindicated in certain individuals, including those with: a
history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactoid
reaction to neomycin; blood dyscrasias, leukemia, lymphomas of any type, or
other malignant neoplasms affecting the bone marrow or lymphatic systems; an
immunodeficient condition or receiving immunosuppressive therapy; active, untreated
tuberculosis; active febrile illness; or those who are pregnant.
In children, adolescents, and adults monitored for up to 42 days, the adverse
effects most frequently reported were as follows: fever, injection-site complaints,
varicella-like rash (injection site), and varicella-like rash (generalized).
In a clinical trial involving children who received 2 doses of VARIVAX 3 months
apart, the incidence of injection-site clinical complaints (primarily erythema
and swelling) observed in the first 4 days following vaccination was slightly
higher post-dose 2 (overall incidence 25.4%) than post-dose 1 (overall incidence
21.7%), whereas the incidence of systemic clinical complaints in the 42-day
follow-up period was lower post-dose 2 (66.3%) than post-dose 1 (85.8%).
Before administering VARIVAX, please read the Prescribing
Information and
Patient
Product Information.
|
